The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer

被引：0
|
作者：
Xia, Yang [1 ]
Huang, Xiu [1 ]
Jin, Rui [1 ]
Li, Wen [1 ]
Shen, Huahao [1 ]
机构：
[1] Zhejiang Univ, Hangzhou, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
D O I：
10.1183/13993003.congress-2019.PA4669
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4669
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The efficacy of ado-trastuzumab emtansine in patients with HER-2-aberrant non-small cell lung cancer.
    Xia, Yang
    Huang, Xiu
    Jin, Rui
    Li, Wen
    Shen, Huahao
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review
    Huang, Xiu
    Jin, Rui
    Lou, Lingyun
    Zhao, Jie
    Xia, Lexin
    Zhao, Jing
    Li, Wen
    Xu, Zhihao
    Xia, Yang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (08) : 4507 - 4516
  • [3] Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer
    Ozyukseler, Deniz Tataroglu
    Basak, Mustafa
    Ay, Seval
    Koseoglu, Aygul
    Arici, Serdar
    Oyman, Abdilkerim
    Surmeli, Heves
    Turan, Merve
    Turan, Nedim
    Odabas, Hatice
    Yildirim, Mahmut E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 547 - 554
  • [4] Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1425): : 75 - 76
  • [5] ADO-TRASTUZUMAB EMTANSINE ACHIEVES RESPONSES IN ERBB2-MUTANT LUNG CANCER
    不详
    CANCER DISCOVERY, 2018, 8 (09) : 1058 - 1058
  • [6] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
    Hotta, Katsuyuki
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Ichihara, Eiki
    Kubo, Toshio
    Ninomiya, Takashi
    Chikamori, Kenichi
    Harada, Daijiro
    Nogami, Naoyuki
    Hirata, Taizo
    Hinotsu, Shiro
    Toyooka, Shinichi
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 273 - 279
  • [7] HER-2 Mutations in Non-Small Cell Lung Cancer
    Sen, Erdem
    Yavas, Guler
    Ata, Ozlem
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
  • [8] Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer
    Chung, Clement
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (10) : 717 - 718
  • [9] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [10] Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers
    Li, B.
    Shen, R.
    Buonocore, D.
    Olah, Z.
    Ni, A.
    Ginsberg, M.
    Ulaner, G.
    Weber, W.
    Tsui, D.
    Offin, M.
    Won, H.
    Ladanyi, M.
    Riely, G.
    Solit, D.
    Hyman, D.
    Rudin, C.
    Berger, M.
    Baselga, J.
    Scaltriti, M.
    Arcila, M.
    Kris, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
12345